Abstract：Three patients (patient 1, a 52-year-old female, with a history of hepatitis; patient 2, a 64-year-old female; patient 3, a 61-year-old female) were all treated with morodan concentrated pill (16 pills, thrice daily for all) for chronic gastritis. In patient 1, there were no combined drugs; in patient 2, sodium rabeprazole enteric-coated tablets were also used; in patient 3, sodium rabeprazole enteric-coated tablets and rebamipide tablets were combined. Patient 1, patient 2, and patient 3 developed abnormal liver function after 27, 22, and 19 days of morodan concentrated pill administration, respectively. Their alanine aminotransferase (ALT) increased by more than 5 times the upper limit of the reference value, accompanied by elevated bilirubin in patient 2 and patient 3. All the 3 patients were stopped to use morodan concentrated pill immediately. After 18, 22, and 24 days of liver-protective treatments, the liver function of patient 1, patient 2, and patient 3 returned to normal, respectively.
